NClip

Thrombolytics

5 min read

Thrombolytics

Key Points

  • Thrombolytics (fibrinolytics) break down existing clots by activating plasminogen → plasmin, which degrades the fibrin clot.
  • Primary agents: alteplase (acute ischemic stroke, STEMI, PE) and tenecteplase (STEMI; off-label stroke use).
  • Strict contraindications apply — active bleeding or recent intracranial surgery are absolute barriers to administration.
  • Bleeding is the primary life-threatening adverse effect; nursing monitoring focuses on hemorrhagic complications.
  • Alteplase has a very short half-life (about 5 minutes) and is also used in low-dose form to clear occluded central/arterial lines.
  • Tenecteplase is commonly faster to prepare and can be given as a single IV bolus without a dedicated infusion pump line.
  • Do not abbreviate alteplase as “tPA” — this notation causes confusion with tenecteplase (TNK) and total parenteral nutrition (TPN).

Mechanism of Action

Thrombolytics facilitate the conversion of plasminogen → plasmin. Plasmin then initiates fibrinolysis — enzymatic breakdown of the fibrin mesh that forms the structural backbone of a thrombus. Unlike anticoagulants, which prevent new clot formation, thrombolytics actively dissolve existing clots and are used when blood flow to a critical organ must be restored rapidly.

Agents and Indications

DrugIndicationsKey Feature
Alteplase (Activase)Acute ischemic stroke (stroke), STEMI, massive PE, and selected occluded line clearanceShort half-life (<5 min); requires dedicated IV line; complicated reconstitution
Tenecteplase (TNKase)STEMI; off-label acute ischemic strokeIV bolus administration; simpler preparation than alteplase; no dedicated infusion pump line required

Alteplase dosing (acute ischemic stroke): 0.9 mg/kg IV (maximum 90 mg total) over 60 minutes; 10% of total dose given as initial bolus over 1 minute.

Abbreviation Safety Alert

Never abbreviate alteplase as “tPA” — this abbreviation is confused with TNK (tenecteplase) and TPN (total parenteral nutrition), both of which have caused serious medication errors and delays. Use the full drug name.

Contraindications

Thrombolytics carry a high risk of bleeding. Absolute contraindications include:

  • Active internal bleeding (other than menstrual)
  • Prior intracranial hemorrhage or hemorrhagic stroke at any time
  • Recent stroke history when outside protocol criteria
  • Recent intracranial or intraspinal surgery or serious head trauma (often within about 2-3 months per protocol/drug)
  • Intracranial neoplasm
  • Arteriovenous malformation or aneurysm
  • Known bleeding diathesis
  • Severe uncontrolled hypertension (increases intracranial hemorrhage risk)

Nursing Assessment

NCLEX Focus

Time is tissue: thrombolytics must be administered within strict time windows (e.g., ≤3–4.5 hours for alteplase in stroke). Pre-administration contraindication screening is the priority nursing action — missing a contraindication can cause fatal intracranial hemorrhage.

Before administration:

  • Obtain complete baseline vital signs; document neurological status (stroke cases)
  • Review complete contraindication checklist — confirm no active bleeding, no recent surgery
  • Review concomitant medications that raise bleeding risk or hypersensitivity concern (anticoagulants, antiplatelets, and selected ACE inhibitors)
  • Obtain head CT before stroke thrombolysis to exclude hemorrhagic stroke or brain tumor contraindications
  • Establish IV access; alteplase requires a dedicated IV line

Nursing Interventions

During infusion:

  • Avoid all intramuscular injections during and after thrombolytic infusion (bleeding risk)
  • Avoid internal jugular and subclavian venous punctures
  • If arterial puncture is unavoidable: use a compressible upper extremity vessel, apply pressure for 30 minutes, monitor puncture site closely
  • Maintain the client on bedrest throughout and after infusion to reduce fall and injury risk
  • Continuous cardiac monitoring during STEMI treatment (reperfusion dysrhythmias)
  • In selected pathways, alteplase may be followed by heparin to reduce reocclusion risk per protocol

After administration:

  • Monitor CBC and observe for signs of bleeding: hematuria, hematemesis, melena, neurological deterioration, hypotension
  • Assess for hypersensitivity reactions (flushing, rash, bronchospasm)
  • Monitor for thromboembolic events in high-risk clients (for example left-heart thrombus risk such as atrial fibrillation)
  • Notify provider immediately if bleeding is suspected
  • In acute ischemic stroke pathways, avoid aspirin and anticoagulants during the first 24 hours after alteplase unless specifically ordered by protocol.
  • Reinforce that patients should not schedule invasive procedures (including dental procedures) without direct provider coordination after thrombolytic exposure.

Client Teaching

  • Report bleeding symptoms immediately and understand disease-specific signs of thrombolytic failure.
  • Remain on bedrest as directed after infusion to reduce fall-related bleeding.
  • Do not stop treatment plans or antithrombotic follow-up medications without provider instruction.
  • Avoid planning elective invasive procedures until the prescribing team confirms safety timing.

Bleeding management:

  • Discontinue infusion if significant hemorrhage occurs
  • Administer cryoprecipitate (blood-derived clotting factors) or antifibrinolytic agents (aminocaproic acid, tranexamic acid) as ordered

Self-Check

  1. A client with acute ischemic stroke has a blood pressure of 200/110 mmHg. Why is this a concern before administering alteplase?
  2. A nurse is preparing to administer alteplase for a STEMI and needs to check blood glucose via finger stick. When should this be done relative to alteplase administration?
  3. What is the significance of alteplase’s short half-life (<5 minutes) in terms of bleeding management?

Graph View